Lawrence C Sowers, Lucas S Blanton, Scott C Weaver, Randall J Urban, Charles P Mouton
The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.
{"title":"Pharmacological approaches to the treatment of COVID-19 patients.","authors":"Lawrence C Sowers, Lucas S Blanton, Scott C Weaver, Randall J Urban, Charles P Mouton","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"6 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543691/pdf/nihms-1604656.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38477197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Farsad Afshinnia, Adil Jadoon, Thekkelnaycke M Rajendiran, Tanu Soni, Jaeman Byun, George Michailidis, Subramaniam Pennathur
Rationale and objective: Despite contribution of dyslipidemia to ischemic stroke, plasma lipidomic correlates of stroke in CKD is not studied. This study is aimed to identify plasma lipid alterations associated with stroke.
Study design: Cross sectional.
Setting and population: 214 participants of Clinical Phenotyping and Resource Biobank Core (CPROBE). Clinical data and plasma samples at the time of recruitment were obtained and used to generate lipidomic data by liquid chromatography/mass-spectrometry-based untargeted platform.
Predictors: Various levels of free fatty acids, acylcarnitines and complex lipids.
Outcome: Stroke.
Analytic approach: includes compound by compound comparison of lipids using t-test adjusted by false discovery rate in patients with and without stroke, and application of logistic regression analysis to identify independent lipid predictors of stroke and to estimate the odds associated with their various levels.
Results: Overall, we identified 330 compounds. Enrichment analysis revealed overrepresentation of differentially regulated phosphatidylcholines (PC)s and phosphatidylethanolamines (PE)s were overrepresented in stroke (P<0.001). Abundance of PC38:4, PE36:4, PC34:0, and palmitate were significantly higher, but those of plasmenyl-PE (pPE)38:2, and PE 32:2 was significantly lower in patients with stroke (p≤0.0014). After adjusting, each 1-SD increase in palmitate and PC38:4 was independently associated with 1.84 fold (95% CI: 1.06-3.20, p=0.031) and 1.84 fold (1.11-3.05, p=0.018) higher risk of stroke, respectively. We observed a significant trend toward higher abundance of PCs, PEs, pPEs, and sphingomyelins in stroke (p≤0.046).
Limitations: Small sample size; unclear, if similar changes in the same or opposite direction preceded stroke, as the cross-sectional nature of the observation does not allow determining the effect of time course on lipid alterations.
Conclusion: Differential regulation of palmitate, PCs, and PEs in patients with CKD and a history of stroke may represent a previously unrecognized risk factor and might be a target of risk stratification and modification.
{"title":"Plasma lipidomic profiling identifies a novel complex lipid signature associated with ischemic stroke in chronic kidney disease.","authors":"Farsad Afshinnia, Adil Jadoon, Thekkelnaycke M Rajendiran, Tanu Soni, Jaeman Byun, George Michailidis, Subramaniam Pennathur","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Rationale and objective: </strong>Despite contribution of dyslipidemia to ischemic stroke, plasma lipidomic correlates of stroke in CKD is not studied. This study is aimed to identify plasma lipid alterations associated with stroke.</p><p><strong>Study design: </strong>Cross sectional.</p><p><strong>Setting and population: </strong>214 participants of Clinical Phenotyping and Resource Biobank Core (CPROBE). Clinical data and plasma samples at the time of recruitment were obtained and used to generate lipidomic data by liquid chromatography/mass-spectrometry-based untargeted platform.</p><p><strong>Predictors: </strong>Various levels of free fatty acids, acylcarnitines and complex lipids.</p><p><strong>Outcome: </strong>Stroke.</p><p><strong>Analytic approach: </strong>includes compound by compound comparison of lipids using t-test adjusted by false discovery rate in patients with and without stroke, and application of logistic regression analysis to identify independent lipid predictors of stroke and to estimate the odds associated with their various levels.</p><p><strong>Results: </strong>Overall, we identified 330 compounds. Enrichment analysis revealed overrepresentation of differentially regulated phosphatidylcholines (PC)s and phosphatidylethanolamines (PE)s were overrepresented in stroke (P<0.001). Abundance of PC38:4, PE36:4, PC34:0, and palmitate were significantly higher, but those of plasmenyl-PE (pPE)38:2, and PE 32:2 was significantly lower in patients with stroke (p≤0.0014). After adjusting, each 1-SD increase in palmitate and PC38:4 was independently associated with 1.84 fold (95% CI: 1.06-3.20, p=0.031) and 1.84 fold (1.11-3.05, p=0.018) higher risk of stroke, respectively. We observed a significant trend toward higher abundance of PCs, PEs, pPEs, and sphingomyelins in stroke (p≤0.046).</p><p><strong>Limitations: </strong>Small sample size; unclear, if similar changes in the same or opposite direction preceded stroke, as the cross-sectional nature of the observation does not allow determining the effect of time course on lipid alterations.</p><p><strong>Conclusion: </strong>Differential regulation of palmitate, PCs, and PEs in patients with CKD and a history of stroke may represent a previously unrecognized risk factor and might be a target of risk stratification and modification.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"6 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38642806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01Epub Date: 2020-01-27DOI: 10.15761/jts.1000374
Meng-Zhao Deng, Mohamed Y Abdelfattah, Michael C Baldwin, Edward M Weaver, Zi-Jun Liu
Objective: Obesity has reached epidemic proportions and is a strong risk factor for obstructive sleep apnea (OSA). However, the underlying mechanisms are poorly understood and current treatment strategies for OSA and obesity have critical limitations. Thus, establishment of an obesity-related large animal model with spontaneous OSA is imperative.
Materials and methods: Natural and sedated sleep were monitored and characterized in 4 obese (body mass index - BMI>48) and 3 non-obese (BMI<40) minipigs. These minipigs were instrumented with the BioRadio system under sedation for the wireless recording of respiratory airflow, snoring, abdominal and chest respiratory movements, electroencephalogram, electrooclulogram, electromyogram, and oxygen saturation. After instrumentation, the minipigs were placed in a dark room with a remote night-vision camera for monitoring all behaviors. Wakefulness and different sleep stages were classified, and episodes of apneas and/or hypopneas were identified during natural and/or sedated sleep.
Results: No hypopnea episodes were observed in two of the non-obese minipigs, but one non-obese minipig had 5 hypopnea events. Heavy snoring and 27-58 apnea and/or hypopnea episodes were identified in all 4 obese minipigs. Most of these episodes occurred in the rapid eye movement stage during natural sleep and/or sedated sleep in Yucatan minipigs.
Conclusions: Obese minipigs can experience naturally occurring OSA, thus are an ideal large animal model for obese-related OSA studies.
{"title":"Obstructive sleep apnea in obese minipigs.","authors":"Meng-Zhao Deng, Mohamed Y Abdelfattah, Michael C Baldwin, Edward M Weaver, Zi-Jun Liu","doi":"10.15761/jts.1000374","DOIUrl":"https://doi.org/10.15761/jts.1000374","url":null,"abstract":"<p><strong>Objective: </strong>Obesity has reached epidemic proportions and is a strong risk factor for obstructive sleep apnea (OSA). However, the underlying mechanisms are poorly understood and current treatment strategies for OSA and obesity have critical limitations. Thus, establishment of an obesity-related large animal model with spontaneous OSA is imperative.</p><p><strong>Materials and methods: </strong>Natural and sedated sleep were monitored and characterized in 4 obese (body mass index - BMI>48) and 3 non-obese (BMI<40) minipigs. These minipigs were instrumented with the BioRadio system under sedation for the wireless recording of respiratory airflow, snoring, abdominal and chest respiratory movements, electroencephalogram, electrooclulogram, electromyogram, and oxygen saturation. After instrumentation, the minipigs were placed in a dark room with a remote night-vision camera for monitoring all behaviors. Wakefulness and different sleep stages were classified, and episodes of apneas and/or hypopneas were identified during natural and/or sedated sleep.</p><p><strong>Results: </strong>No hypopnea episodes were observed in two of the non-obese minipigs, but one non-obese minipig had 5 hypopnea events. Heavy snoring and 27-58 apnea and/or hypopnea episodes were identified in all 4 obese minipigs. Most of these episodes occurred in the rapid eye movement stage during natural sleep and/or sedated sleep in Yucatan minipigs.</p><p><strong>Conclusions: </strong>Obese minipigs can experience naturally occurring OSA, thus are an ideal large animal model for obese-related OSA studies.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"6 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38553473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AC Sylvetsky, V. Bauman, J. Abdelhadi, JE Blau, K.R. Wilkins, KI Rother
Objective: To determine whether sex, age, and body mass index are correlated with active glucagon-like-peptide 1 concentrations and to investigate glucagon-like-peptide 1 reproducibility during repeated oral glucose tolerance tests. Methods: Sixty-one healthy volunteers underwent four 2-hour repeated oral glucose tolerance tests approximately 1 week apart. Because this randomized same-subject crossover trial was designed to investigate effects of non-nutritive sweeteners, participants received 355 mL (12 ounces) of water or a beverage containing non-nutritive sweeteners 10 minutes prior to each oral glucose tolerance test. Blood samples were collected 10 minutes before, and 0, 10, 20, 30, 60, 90, and 120 minutes following ingestion of 75 grams of glucose. Results: Basal active glucagon-like-peptide 1, peak glucagon-like-peptide 1, and glucagon-like-peptide 1 area-under-the-curve were higher in men than women (all p ≤0.04), adjusting for body mass index and age. Fasting and stimulated active glucagon-like-peptide 1 results were highly reproducible with little within-subject variability (between-subjects to within-subject variability ratio 4.2 and 3.5 for fasting glucagon-like-peptide 1 and glucagon-like-peptide 1 area-under-the-curve). Conclusion: Men had higher active glucagon-like-peptide 1 concentrations than women. In contrast to considerable inter-individual variability of basal and stimulated active glucagon-like-peptide 1 concentrations, intra-individual variability was low, consistent with tight physiological regulation.
{"title":"Inter- and intra-individual variability of active glucagon-like peptide 1 among healthy adults","authors":"AC Sylvetsky, V. Bauman, J. Abdelhadi, JE Blau, K.R. Wilkins, KI Rother","doi":"10.15761/jts.1000404","DOIUrl":"https://doi.org/10.15761/jts.1000404","url":null,"abstract":"Objective: To determine whether sex, age, and body mass index are correlated with active glucagon-like-peptide 1 concentrations and to investigate glucagon-like-peptide 1 reproducibility during repeated oral glucose tolerance tests. Methods: Sixty-one healthy volunteers underwent four 2-hour repeated oral glucose tolerance tests approximately 1 week apart. Because this randomized same-subject crossover trial was designed to investigate effects of non-nutritive sweeteners, participants received 355 mL (12 ounces) of water or a beverage containing non-nutritive sweeteners 10 minutes prior to each oral glucose tolerance test. Blood samples were collected 10 minutes before, and 0, 10, 20, 30, 60, 90, and 120 minutes following ingestion of 75 grams of glucose. Results: Basal active glucagon-like-peptide 1, peak glucagon-like-peptide 1, and glucagon-like-peptide 1 area-under-the-curve were higher in men than women (all p ≤0.04), adjusting for body mass index and age. Fasting and stimulated active glucagon-like-peptide 1 results were highly reproducible with little within-subject variability (between-subjects to within-subject variability ratio 4.2 and 3.5 for fasting glucagon-like-peptide 1 and glucagon-like-peptide 1 area-under-the-curve). Conclusion: Men had higher active glucagon-like-peptide 1 concentrations than women. In contrast to considerable inter-individual variability of basal and stimulated active glucagon-like-peptide 1 concentrations, intra-individual variability was low, consistent with tight physiological regulation.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48969486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-01Epub Date: 2019-06-24DOI: 10.15761/jts.1000341
Ahmad R Safa
Human cancers emerge from cancer stem cells (CSCs), which are resistant to cancer chemotherapeutic agents, radiation, and cell death. Moreover, autophagy provides the cytoprotective effect which contributes to drug resistance in these cells. Furthermore, much evidence shows that CSCs cause tumor initiation, progression, metastasis, and cancer recurrence. Various signaling pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), maternal embryonic leucine zipper kinase (MELK), NOTCH1, and Wnt/β-catenin as well as the CSC markers maintain CSC properties. Several mechanisms including overexpression of ABC multidrug resistance transporters, a deficiency in mitochondrial-mediated apoptosis, upregulation of c-FLIP, overexpression of anti-apoptotic Bcl-2 family members and inhibitors of apoptosis proteins (IAPs), and PI3K/AKT signaling contribute to enhancing resistance to chemotherapeutic drugs and cell death induction in CSCs in various cancers. Studying such pathways may help provide detailed understanding of CSC mechanisms of resistance to chemotherapeutic agents and apoptosis and may lead to the development of effective therapeutics to eradicate CSCs.
{"title":"Resistance to drugs and cell death in cancer stem cells (CSCs).","authors":"Ahmad R Safa","doi":"10.15761/jts.1000341","DOIUrl":"https://doi.org/10.15761/jts.1000341","url":null,"abstract":"<p><p>Human cancers emerge from cancer stem cells (CSCs), which are resistant to cancer chemotherapeutic agents, radiation, and cell death. Moreover, autophagy provides the cytoprotective effect which contributes to drug resistance in these cells. Furthermore, much evidence shows that CSCs cause tumor initiation, progression, metastasis, and cancer recurrence. Various signaling pathways including the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), maternal embryonic leucine zipper kinase (MELK), NOTCH1, and Wnt/β-catenin as well as the CSC markers maintain CSC properties. Several mechanisms including overexpression of ABC multidrug resistance transporters, a deficiency in mitochondrial-mediated apoptosis, upregulation of c-FLIP, overexpression of anti-apoptotic Bcl-2 family members and inhibitors of apoptosis proteins (IAPs), and PI3K/AKT signaling contribute to enhancing resistance to chemotherapeutic drugs and cell death induction in CSCs in various cancers. Studying such pathways may help provide detailed understanding of CSC mechanisms of resistance to chemotherapeutic agents and apoptosis and may lead to the development of effective therapeutics to eradicate CSCs.</p>","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"6 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40325664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Afshinnia, A. Jadoon, Thekkelnaycke M. Rajendiran, Tanu Soni, Jaeman Byun, G. Michailidis, S. Pennathur
Rationale and objective: Despite contribution of dyslipidemia to ischemic stroke, plasma lipidomic correlates of stroke in CKD is not studied. This study is aimed to identify plasma lipid alterations associated with stroke. Study design: Cross sectional. Setting and population: 214 participants of Clinical Phenotyping and Resource Biobank Core (CPROBE). Clinical data and plasma samples at the time of recruitment were obtained and used to generate lipidomic data by liquid chromatography/mass-spectrometry-based untargeted platform. Predictors: Various levels of free fatty acids, acylcarnitines and complex lipids. Outcome: Stroke. Analytic approach: includes compound by compound comparison of lipids using t-test adjusted by false discovery rate in patients with and without stroke, and application of logistic regression analysis to identify independent lipid predictors of stroke and to estimate the odds associated with their various levels. Results: Overall, we identified 330 compounds. Enrichment analysis revealed overrepresentation of differentially regulated phosphatidylcholines (PC)s and phosphatidylethanolamines (PE)s were overrepresented in stroke (P<0.001). Abundance of PC38:4, PE36:4, PC34:0, and palmitate were significantly higher, but those of plasmenyl-PE (pPE)38:2, and PE 32:2 was significantly lower in patients with stroke (p≤0.0014). After adjusting, each 1-SD increase in palmitate and PC38:4 was independently associated with 1.84 fold (95% CI: 1.06–3.20, p=0.031) and 1.84 fold (1.11–3.05, p=0.018) higher risk of stroke, respectively. We observed a significant trend toward higher abundance of PCs, PEs, pPEs, and sphingomyelins in stroke (p≤0.046). Limitations: Small sample size; unclear, if similar changes in the same or opposite direction preceded stroke, as the cross-sectional nature of the observation does not allow determining the effect of time course on lipid alterations. Conclusion: Differential regulation of palmitate, PCs, and PEs in patients with CKD and a history of stroke may represent a previously unrecognized risk factor and might be a target of risk stratification and modification.
{"title":"Plasma lipidomic profiling identifies a novel complex lipid signature associated with ischemic stroke in chronic kidney disease","authors":"F. Afshinnia, A. Jadoon, Thekkelnaycke M. Rajendiran, Tanu Soni, Jaeman Byun, G. Michailidis, S. Pennathur","doi":"10.15761/JTS.1000419","DOIUrl":"https://doi.org/10.15761/JTS.1000419","url":null,"abstract":"Rationale and objective: Despite contribution of dyslipidemia to ischemic stroke, plasma lipidomic correlates of stroke in CKD is not studied. This study is aimed to identify plasma lipid alterations associated with stroke. Study design: Cross sectional. Setting and population: 214 participants of Clinical Phenotyping and Resource Biobank Core (CPROBE). Clinical data and plasma samples at the time of recruitment were obtained and used to generate lipidomic data by liquid chromatography/mass-spectrometry-based untargeted platform. Predictors: Various levels of free fatty acids, acylcarnitines and complex lipids. Outcome: Stroke. Analytic approach: includes compound by compound comparison of lipids using t-test adjusted by false discovery rate in patients with and without stroke, and application of logistic regression analysis to identify independent lipid predictors of stroke and to estimate the odds associated with their various levels. Results: Overall, we identified 330 compounds. Enrichment analysis revealed overrepresentation of differentially regulated phosphatidylcholines (PC)s and phosphatidylethanolamines (PE)s were overrepresented in stroke (P<0.001). Abundance of PC38:4, PE36:4, PC34:0, and palmitate were significantly higher, but those of plasmenyl-PE (pPE)38:2, and PE 32:2 was significantly lower in patients with stroke (p≤0.0014). After adjusting, each 1-SD increase in palmitate and PC38:4 was independently associated with 1.84 fold (95% CI: 1.06–3.20, p=0.031) and 1.84 fold (1.11–3.05, p=0.018) higher risk of stroke, respectively. We observed a significant trend toward higher abundance of PCs, PEs, pPEs, and sphingomyelins in stroke (p≤0.046). Limitations: Small sample size; unclear, if similar changes in the same or opposite direction preceded stroke, as the cross-sectional nature of the observation does not allow determining the effect of time course on lipid alterations. Conclusion: Differential regulation of palmitate, PCs, and PEs in patients with CKD and a history of stroke may represent a previously unrecognized risk factor and might be a target of risk stratification and modification.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43047889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Sowers, L. Blanton, S. Weaver, R. Urban, Charles P. Mouton
The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.
{"title":"Pharmacological approaches to the treatment of COVID-19 patients.","authors":"L. Sowers, L. Blanton, S. Weaver, R. Urban, Charles P. Mouton","doi":"10.15761/JTS.1000394","DOIUrl":"https://doi.org/10.15761/JTS.1000394","url":null,"abstract":"The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"6 6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43674504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate continues performance of selfmonitoring blood glucose (SMBG) systems [1]. In addition, publication of such studies is increasingly becoming a component of evidence-based purchase decision making. ISO 15197:2015, [2] for which mandatory compliance is recommended for SMBG systems by 2015, [3] has tighter accuracy requirements than ISO 15197:2003, [4] and outlines current minimum accuracy standards necessary in Europe for CE marking. In the present study, a postmarketing evaluation of the CE-marked GL50 evo and GL44 systems were performed in accordance with ISO 15197:2015 protocols and requirements. The GL50 evo and GL44 systems were supplied in Germany from the Beurer GmbH, Germany. A declaration of conformity from the manufacturer of the two measuring systems was available before the start of the study, so that only the GL50 evo was used in the tests, but the results documented the quality of bothsystems. Two GL50 evo systems (serial number: GL55 T1 and GL55 T2) and strips from 3 different lots (A 10/1, A 10/3,A 10/4) with expiry dates March 2017 respectively) were supplied by the manufacturer. The study was
{"title":"System accuracy evaluation of the systems for selfmonitoring of blood glucose GL50 evo and GL 44 following DIN EN ISO 15197:2015 – A comparison of accuracy in hypo (<70 mg/dL)- and hyper glycemic (≥180 mg/dL) glucose ranges","authors":"E. Salzsieder, A. Puchert, EJ Freyse, S. Berg","doi":"10.15761/JTS.1000348","DOIUrl":"https://doi.org/10.15761/JTS.1000348","url":null,"abstract":"Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate continues performance of selfmonitoring blood glucose (SMBG) systems [1]. In addition, publication of such studies is increasingly becoming a component of evidence-based purchase decision making. ISO 15197:2015, [2] for which mandatory compliance is recommended for SMBG systems by 2015, [3] has tighter accuracy requirements than ISO 15197:2003, [4] and outlines current minimum accuracy standards necessary in Europe for CE marking. In the present study, a postmarketing evaluation of the CE-marked GL50 evo and GL44 systems were performed in accordance with ISO 15197:2015 protocols and requirements. The GL50 evo and GL44 systems were supplied in Germany from the Beurer GmbH, Germany. A declaration of conformity from the manufacturer of the two measuring systems was available before the start of the study, so that only the GL50 evo was used in the tests, but the results documented the quality of bothsystems. Two GL50 evo systems (serial number: GL55 T1 and GL55 T2) and strips from 3 different lots (A 10/1, A 10/3,A 10/4) with expiry dates March 2017 respectively) were supplied by the manufacturer. The study was","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liping Xuan, Jun Ma, Mei Yu, Zhenxing Yang, Yongmin Huang, Caiyun Guo, Yang Lu, Lidan Yan, Songqing Shi
Aim: Insulin-like growth factor-2 (IGF2) is known to regulate fetal development and differentiation, but its role in adults is still poorly understood compared with that of IGF1. This study evaluated the expression of IGF2 in obesity with type 2 diabetes mellitus (T2DM) and investigated the effects of IGF2 on adipocyte proliferation, differentiation and lipid deposition. Methods: A cross-sectional study with pair-matched controls was conducted on 50 adults with obese T2DM and 50 controls in Yuyao people's hospital, China. Serum levels of IGF2 were measured with a commercial ELISA kit. Pre-adipocytes of 3T3-L1 cell viability was determined by an MTS assay. Oil Red O staining and Nile Red staining were performed to evaluate the effects of IGF2 on 3T3-L1 differentiation and lipid deposition. Results: The expression of IGF2 is up-regulated in obese T2DM and correlates with lipid-related parameters like body mass index (r=0.315, p=0.002), waist circumference (r=0.271, p=0.008), triglyceride (r=0.262, p=0.008) and HDL-c (r=-0.324, p=0.002). Treatment of IGF2 could promote the proliferation of 3T3-L1 cells in a dose-dependent manner. High dose of IGF2 promoted 3T3-L1 differentiation by Oil Red O staining and enhanced the lipid accumulation in differentiated 3T3-L1 adipocytes by Nile Red staining and triglyceride assay. Conclusion: High level of IGF2 was positively correlated with lipid-related parameters in obeseT2DM. Furthermore, IGF2 could promote the proliferation and differentiation of 3T3-L1 cells and increase the lipid deposition of differentiated 3T3-L1 adipocytes.
{"title":"Insulin-like growth factor 2 promotes adipocyte proliferation, differentiation and lipid deposition in obese type 2 diabetes","authors":"Liping Xuan, Jun Ma, Mei Yu, Zhenxing Yang, Yongmin Huang, Caiyun Guo, Yang Lu, Lidan Yan, Songqing Shi","doi":"10.15761/jts.1000362","DOIUrl":"https://doi.org/10.15761/jts.1000362","url":null,"abstract":"Aim: Insulin-like growth factor-2 (IGF2) is known to regulate fetal development and differentiation, but its role in adults is still poorly understood compared with that of IGF1. This study evaluated the expression of IGF2 in obesity with type 2 diabetes mellitus (T2DM) and investigated the effects of IGF2 on adipocyte proliferation, differentiation and lipid deposition. Methods: A cross-sectional study with pair-matched controls was conducted on 50 adults with obese T2DM and 50 controls in Yuyao people's hospital, China. Serum levels of IGF2 were measured with a commercial ELISA kit. Pre-adipocytes of 3T3-L1 cell viability was determined by an MTS assay. Oil Red O staining and Nile Red staining were performed to evaluate the effects of IGF2 on 3T3-L1 differentiation and lipid deposition. Results: The expression of IGF2 is up-regulated in obese T2DM and correlates with lipid-related parameters like body mass index (r=0.315, p=0.002), waist circumference (r=0.271, p=0.008), triglyceride (r=0.262, p=0.008) and HDL-c (r=-0.324, p=0.002). Treatment of IGF2 could promote the proliferation of 3T3-L1 cells in a dose-dependent manner. High dose of IGF2 promoted 3T3-L1 differentiation by Oil Red O staining and enhanced the lipid accumulation in differentiated 3T3-L1 adipocytes by Nile Red staining and triglyceride assay. Conclusion: High level of IGF2 was positively correlated with lipid-related parameters in obeseT2DM. Furthermore, IGF2 could promote the proliferation and differentiation of 3T3-L1 cells and increase the lipid deposition of differentiated 3T3-L1 adipocytes.","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The extracellular matrix (ECM) provides the three-dimensional structure of tissues, and is required for cell homing and cell viability, as well as for the overall homeostasis of tissues and organs [1,2]. The dynamic and complex microenvironment that the ECM generates in a specific manner for each tissue guarantees its functions [1,2]. During tissue regeneration ECM has been shown to play an essential role in controlling the tissue-stem cell compartment and to be involved in tissue regeneration outcome [3-6]. Tissue engineering combines extracellular natural and/or synthetic scaffolds (biomaterials) with stem cells and growth factors for the development of regenerative medicine strategies and the treatment of diseased tissues [7]. Despite the fact that incredible improvements have been achieved in biomaterial manufacturing, the peculiar and complex biochemistry, biomechanics and 3D organization proper of a tissue-specific ECM still cannot totally be reproduced in the lab [1,2,8]. Such complexity can however be preserved in scaffolds that take advantage of the native tissue themselves, as decellularized tissues or whole organs [9-11]. Decellularization process remove cellular and nuclear content retaining ECM mechanical integrity, biological activity and 3D architecture of the native tissue [10]. Decellularized tissues and/or organs represent alternative and promising scaffold material for the treatment of clinical cases in which extensive regeneration of an organ is required, as in cases of traumatic injuries, surgical ablation and congenital diseases [12]. Decellularized scaffolds have already been obtained from different organs and used for regenerative medicine strategies in animal models, as well as in clinical trials [12,13]. Ideally
{"title":"Decellularized scaffolds for neuronal regeneration","authors":"P. Raffa, A. Urciuolo","doi":"10.15761/JTS.1000371","DOIUrl":"https://doi.org/10.15761/JTS.1000371","url":null,"abstract":"The extracellular matrix (ECM) provides the three-dimensional structure of tissues, and is required for cell homing and cell viability, as well as for the overall homeostasis of tissues and organs [1,2]. The dynamic and complex microenvironment that the ECM generates in a specific manner for each tissue guarantees its functions [1,2]. During tissue regeneration ECM has been shown to play an essential role in controlling the tissue-stem cell compartment and to be involved in tissue regeneration outcome [3-6]. Tissue engineering combines extracellular natural and/or synthetic scaffolds (biomaterials) with stem cells and growth factors for the development of regenerative medicine strategies and the treatment of diseased tissues [7]. Despite the fact that incredible improvements have been achieved in biomaterial manufacturing, the peculiar and complex biochemistry, biomechanics and 3D organization proper of a tissue-specific ECM still cannot totally be reproduced in the lab [1,2,8]. Such complexity can however be preserved in scaffolds that take advantage of the native tissue themselves, as decellularized tissues or whole organs [9-11]. Decellularization process remove cellular and nuclear content retaining ECM mechanical integrity, biological activity and 3D architecture of the native tissue [10]. Decellularized tissues and/or organs represent alternative and promising scaffold material for the treatment of clinical cases in which extensive regeneration of an organ is required, as in cases of traumatic injuries, surgical ablation and congenital diseases [12]. Decellularized scaffolds have already been obtained from different organs and used for regenerative medicine strategies in animal models, as well as in clinical trials [12,13]. Ideally","PeriodicalId":74000,"journal":{"name":"Journal of translational science","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67490758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}